CytomX Therapeutics (CTMX) Leases (2017 - 2025)
CytomX Therapeutics (CTMX) has disclosed Leases for 9 consecutive years, with $4.8 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Leases fell 47.63% year-over-year to $4.8 million, compared with a TTM value of $4.8 million through Sep 2025, down 47.63%, and an annual FY2024 reading of $8.1 million, down 33.42% over the prior year.
- Leases was $4.8 million for Q3 2025 at CytomX Therapeutics, down from $5.9 million in the prior quarter.
- Across five years, Leases topped out at $21.7 million in Q1 2021 and bottomed at $4.8 million in Q3 2025.
- Average Leases over 5 years is $13.8 million, with a median of $14.1 million recorded in 2023.
- The sharpest move saw Leases soared 1020.49% in 2021, then tumbled 47.63% in 2025.
- Year by year, Leases stood at $19.4 million in 2021, then dropped by 17.63% to $15.9 million in 2022, then dropped by 23.38% to $12.2 million in 2023, then tumbled by 33.42% to $8.1 million in 2024, then plummeted by 40.83% to $4.8 million in 2025.
- Business Quant data shows Leases for CTMX at $4.8 million in Q3 2025, $5.9 million in Q2 2025, and $7.1 million in Q1 2025.